Published in J Hepatol on November 01, 2004
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (2011) 1.56
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol (2010) 1.36
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med (2009) 1.31
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol (2010) 1.29
Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. J Virol (2010) 1.23
Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology (2007) 1.23
Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol (2007) 1.19
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell (2014) 1.10
Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology (2007) 1.06
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med (2007) 1.05
Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol Appl Pharmacol (2006) 1.02
Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation. J Exp Clin Cancer Res (2010) 0.97
Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol (2010) 0.96
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin (2010) 0.95
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest (2013) 0.93
Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer (2007) 0.92
Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol (2013) 0.92
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med (2011) 0.91
Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer (2013) 0.90
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control. Int J Hepatol (2012) 0.88
Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. BMC Cancer (2011) 0.87
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J (2013) 0.87
Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol (2010) 0.86
Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol (2014) 0.86
Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J Gastroenterol (2013) 0.86
IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol (2015) 0.85
Prognostic significance of preoperative peripheral blood monocyte ratio in patients with hepatocellular carcinoma. World J Surg (2014) 0.85
Vascular biology and pathobiology of the liver: Report of a single-topic symposium. Hepatology (2008) 0.85
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.84
AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma. Oncotarget (2014) 0.84
Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int (2010) 0.84
Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol (2010) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther (2009) 0.82
Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys (2012) 0.82
Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol (2006) 0.82
Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma. PLoS One (2014) 0.81
Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model. PLoS One (2011) 0.81
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol (2016) 0.81
Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.80
Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell. PLoS One (2014) 0.80
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One (2014) 0.80
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol (2016) 0.80
Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int (2014) 0.79
Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. Langenbecks Arch Surg (2008) 0.79
Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med (2011) 0.79
Quantitative in vivo optical tomography of cancer progression & vasculature development in adult zebrafish. Oncotarget (2016) 0.79
Tc17 cells in patients with uterine cervical cancer. PLoS One (2014) 0.79
Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid (2014) 0.78
MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2α. PLoS One (2013) 0.78
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol (2016) 0.78
Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma. J Gastroenterol (2012) 0.78
Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol (2013) 0.78
Interleukin-17A Plays a Pivotal Role in Chemically Induced Hepatocellular Carcinoma in Mice. Dig Dis Sci (2016) 0.78
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine (2016) 0.77
Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. Ann Surg Oncol (2010) 0.77
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. Virchows Arch (2015) 0.77
Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol (2012) 0.77
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Mol Ther (2015) 0.77
Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea. Chin Med (2013) 0.76
Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imaging. PLoS One (2014) 0.75
Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma. World J Gastroenterol (2009) 0.75
RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma. Oncotarget (2017) 0.75
A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery. Drug Des Devel Ther (2016) 0.75
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clin J Gastroenterol (2014) 0.75
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway. PLoS One (2015) 0.75
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol (2016) 0.75
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci (2016) 0.75
Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clin Transl Gastroenterol (2017) 0.75
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75
Gene Expression Profiling of Hepatocellular Carcinoma Derived Cancer Stem Like Cell under Hypoxia. Yonsei Med J (2017) 0.75
Liposome-mediated gene transfer of K1-5 suppresses tumor development and improves the prognosis of hepatocellular carcinoma in mice. Med Mol Morphol (2006) 0.75
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol (2012) 2.07
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24
Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) (2009) 1.22
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol (2011) 1.19
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol (2005) 1.17
Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg (2002) 1.16
The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci (2004) 1.14
Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology (2002) 1.11
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol (2008) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011) 1.06
Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol (2012) 1.06
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One (2013) 0.97
Extended preservation of rat liver graft by induction of heme oxygenase-1. Hepatology (2002) 0.95
Hit proteins, mitochondria and cancer. Biochim Biophys Acta (2011) 0.95
Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology (2006) 0.94
Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int (2007) 0.94
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int (2014) 0.93
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int (2007) 0.92
Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function. Hepatology (2013) 0.91
Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int (2009) 0.90
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology (2012) 0.90
Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol (2004) 0.89
Expression and regulation of gap junctions in rat cholangiocytes. Hepatology (2002) 0.88
Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med Wkly (2013) 0.88
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol (2013) 0.87
[Non-alcoholic steatohepatitis - from NAFLD to MAFLD]. Ther Umsch (2011) 0.87
Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol (2013) 0.86
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int (2013) 0.86
Liver surgery in the era of tissue-preserving resections: early and late outcome in patients with primary and secondary hepatic tumors. World J Surg (2002) 0.85
Hint2 is expressed in the mitochondria of H295R cells and is involved in steroidogenesis. Endocrinology (2008) 0.85
Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. Med Hypotheses (2004) 0.85
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clin Sci (Lond) (2014) 0.84
Ablation of the tumor suppressor histidine triad nucleotide binding protein 1 is protective against hepatic ischemia/reperfusion injury. Hepatology (2010) 0.83
Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) (2010) 0.83
Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly (2002) 0.82
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly (2008) 0.82
Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. J Hepatol (2007) 0.82
Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target (2007) 0.82
UDCA for NASH: end of the story? J Hepatol (2010) 0.81
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clin Sci (Lond) (2014) 0.81
Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease. World J Gastroenterol (2013) 0.80
TACE with or without systemic therapy? J Hepatol (2012) 0.79
Modern hepatomancy. Gastroenterology (2013) 0.79
Disproportionally high results of transient elastography in patients with autoimmune hepatitis. Liver Int (2008) 0.79
PI(3)K/PTEN/AKT pathway. J Hepatol (2010) 0.79
C-reactive protein, a prognostic marker in hepatocellular carcinoma. Hepatology (2013) 0.78
Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. Hepatology (2005) 0.78
Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis: a report of two cases. Eur J Gastroenterol Hepatol (2003) 0.78
Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide. J Biol Chem (2003) 0.78
Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol (2008) 0.78
NASH and thiazolidinediones: not to be taken lightly. J Hepatol (2007) 0.78
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol (2006) 0.78
Targeting vessels to treat hepatocellular carcinoma. Clin Sci (Lond) (2008) 0.77
Characterization of the effect of the mitochondrial protein Hint2 on intracellular Ca(2+) dynamics. Biophys J (2013) 0.77
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly (2003) 0.76
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly (2012) 0.76
Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation. Transpl Int (2007) 0.76
The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin Liver Dis (2013) 0.76
Acute ophthalmoparesis associated with human parvovirus B19 infection. Eur J Ophthalmol (2011) 0.76
Liver allocation in Switzerland. Liver Transpl (2002) 0.75
Abnormal nitrosothiol metabolism in hepatocellular carcinoma. J Hepatol (2010) 0.75
Treat the bones and get less rejection! Liver Int (2009) 0.75
Cholestasis shuts down calcium signaling in cholangiocytes. Hepatology (2004) 0.75
[Liver transplantation - when and for whom it should be performed]. Ther Umsch (2011) 0.75
Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. J Gastroenterol Hepatol (2015) 0.75
Hepatology highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation. Liver Transpl (2005) 0.75
Hepatology highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
[Hepatology scores]. Ther Umsch (2013) 0.75
Hepatology highlights. Hepatology (2015) 0.75
Hepatology highlights. Hepatology (2016) 0.75
Nontumoral dermatologic problems after liver transplantation. Liver Transpl (2004) 0.75
[Treatment of nonalcoholic steatohepatitis]. Rev Prat (2012) 0.75
Hepatology Highlights. Hepatology (2016) 0.75
Hepatology highlights. Hepatology (2015) 0.75
Transplantation for alcoholic liver disease: the wrong arguments. Swiss Med Wkly (2002) 0.75
Hepatology Highlights. Hepatology (2016) 0.75
Treatment of Non-Alcoholic Fatty Liver Disease. Dig Dis (2016) 0.75
Hepatology Highlights. Hepatology (2016) 0.75
Hepatology highlights. Hepatology (2015) 0.75
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Eur J Gastroenterol Hepatol (2016) 0.75
Macro-AST in an asymptomatic young patient. Ann Hepatol (2010) 0.75
Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. Ann Surg (2017) 0.75
Hepatology highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology highlights. Hepatology (2016) 0.75